News & Articles

FEATURED ARTICLE

MRGPRX2: A Promising Target for Antibody Discovery in Allergy and Pain Disorders

Recent studies have shown that various drugs, including small molecules, opioids, and antibiotics, can activate MRGPRX2 (Mas-related G-protein coupled receptor X2), leading to mast cell degranulation and...

Browse articles by topic:

Activin Signaling Pathway: Therapeutic Potential Across Disease Frontiers

November 25, 2024

7 min read

What if a single cellular pathway could unlock new therapies for muscle regeneration, cancer, obesity, immune system regulation, and more?...

NK Cell Therapy Gets IND FDA Clearance with AccuBase® Base Editor from KACTUS

November 21, 2024

5 min read

November 14, 2024 Base Therapeutics announced that its independently developed NK510 cell injection, the world's first base-edited universal NK cell...

2024 Milestones in CRISPR Clinical Pipelines

November 11, 2024

6 min read

With the first CRISPR gene-editing drug approved for over ten months now, what exciting developments are there in CRISPR drug...

MRGPRX2: A Promising Target for Antibody Discovery in Allergy and Pain Disorders

October 28, 2024

5 min read

Recent studies have shown that various drugs, including small molecules, opioids, and antibiotics, can activate MRGPRX2 (Mas-related G-protein coupled receptor...

Base Editing vs. CRISPR: Navigating Precision Gene Therapy

October 14, 2024

5 min read

Gene therapy is marking new frontiers with the recent FDA approvals of innovative treatments for sickle cell disease (SCD). Casgevy...

VLP Antibody Discover

October 2, 2024

4 min read

How VLPs are unlocking the next generation of antibody therapeutics for challenging transmembrane proteins Transmembrane proteins play crucial roles in...

Rethinking Refolding: The Case for Mammalian-Expressed Single-Chain Trimer MHCs

September 18, 2024

5 min read

For years, recombinant major histocompatibility complexes (MHCs) have been expressed in bacterial systems with in vitro refolding. While this preserves...

Virus-Like Particles (VLPs): Understanding their Structure, Expression, and Role in Immune Response

August 28, 2024

7 min read

What are virus-like particles (VLPs)? Virus-like particles (VLPs) are nanoparticle structures (50-300nm diameter) that mimic the organization and conformation of...

Neoantigen-Based Immunotherapy: Unveiling Disease-Specific Targets

August 20, 2024

3 min read

Introducing Neoantigen-Based Immunotherapy Neoantigen-based immunotherapy is revolutionizing cancer treatment by focusing on neoantigens—unique proteins formed by mutations in cancer cells....

AccuBase™ Base Editor Continues to Advance NK Cell Therapies

July 31, 2024

3 min read

After successful IND approval this past July, we are excited to announce the NK therapy NK510 received clinical trial approval from...

IND Approval for Solid Tumor Therapy Using KACTUS Cas9 Enzyme

July 24, 2024

4 min read

In a groundbreaking development for the biotech industry, KACTUS's GMP-grade Cas9 has critically helped Yizun Bio secure IND clearance for a universal...

The Ideal Choice for Low dsRNA: MaxPure™ T7 RNA Polymerase

July 16, 2024

7 min read

Exciting news of mRNA vaccine research against monkeypox has been coming out since the beginning of 2024: February 15, the...

1 2 3 5